Latest Articles
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer - OncLive
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer OncLive
Published: April 8, 2024, 7 a.m.
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer - OncLive
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer OncLive
Published: April 2, 2024, 7 a.m.
Link copied to clipboard!